Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799

被引：0
|
作者：
Reck, M. [1 ]
Lee, K. H. [2 ]
Frost, N. [3 ,4 ,5 ,6 ]
Kowalski, D. M. [7 ]
Breder, V. [8 ]
Pollock, T. [9 ]
Reguart, N. [10 ]
Houghton, B. [11 ]
Quantin, X. [12 ]
Keller, S. M. [13 ]
Liu, H. [13 ]
Piperdi, B. [13 ]
Jabbour, S. K. [14 ]
机构：
[1] German Ctr Lung Res, Airway Res Ctr North, Lungenclin, Grosshansdorf, Germany
[2] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[3] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany
[4] Free Univ Berlin, Berlin, Germany
[5] Humboldt Univ, Berlin, Germany
[6] Berlin Inst Hlth, Berlin, Germany
[7] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[9] Southwestern Reg Med Ctr Inc, Canc Treatment Ctr Amer, Tulsa, OK USA
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Port Macquarie Base Hosp, Mid North Coast Canc Inst, Port Macquarie, NSW, Australia
[12] Montpellier Canc Inst, Dept Med Oncol, Montpellier, France
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
nonesmall-cell lung cancer; Pembrolizumab; chemoradiation therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.03
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [41] KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC
    Cho, B. C.
    Wu, Y.
    Lopes, G.
    Kudaba, I.
    Kowalski, D. M.
    Turna, H. Z.
    De Castro, G., Jr.
    Caglevic, C.
    Zhang, L.
    Karaszewska, B.
    Laktionov, K. K.
    Srimuninnimit, V.
    Bondarenko, I.
    Kubota, K.
    Yin, L.
    Lin, J.
    Souza, F.
    Mok, T. S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S225 - S226
  • [42] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Reynier, M. A. Mouret
    Ferreira, M. I. R.
    Im, S. A.
    Cardoso, F.
    Ding, Y.
    Pan, W.
    Tryfonidis, K. E.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
  • [43] Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407
    Powell, Steven F.
    Rodriguez-Abreu, Delvys
    Langer, Corey J.
    Tafreshi, Ali
    Paz-Ares, Luis
    Kopp, Hans-Georg
    Rodriguez-Cid, Jeronimo
    Kowalski, Dariusz M.
    Cheng, Ying
    Kurata, Takayasu
    Awad, Mark M.
    Lin, Jinaxin
    Zhao, Bin
    Pietanza, M. Catherine
    Piperdi, Bilal
    Garassino, Marina C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1883 - 1892
  • [44] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [45] TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC
    Levy, B.
    Leventakos, K.
    Lou, Y.
    Savvides, P.
    Rixe, O.
    Tolcher, A.
    Yin, J.
    Xie, J.
    Guevara, F.
    Goto, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1097 - S1098
  • [46] Combined radiotherapy - Chemotherapy with vinorelbine in locally advanced, inoperable non small cell lung cancer (NSCLC) stage IIIB
    Vomvas, D.
    Pomoni, M.
    Kardamakis, D.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S301 - S301
  • [47] Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas
    Beauvillain, C
    Mahe, M
    Bourdin, S
    Peuvrel, P
    Bergerot, P
    Riviere, A
    Vignoud, J
    Deraucourt, D
    Wesoluch, M
    LARYNGOSCOPE, 1997, 107 (05): : 648 - 653
  • [48] Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC
    Cheng, Y.
    Zhang, L.
    Hu, J.
    Wang, D.
    Hu, C.
    Zhou, J.
    Wu, L.
    Cao, L.
    Liu, J.
    Zhang, H.
    Sun, H.
    Wang, Z.
    Gao, H.
    Ge, J.
    Wang, H.
    Tian, Y.
    Piperdi, B.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
    Kojima, Takashi
    Shah, Manish A.
    Muro, Kei
    Francois, Eric
    Adenis, Antoine
    Hsu, Chih-Hung
    Doi, Toshihiko
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Bennouna, Jaafar
    Kato, Ken
    Shen, Lin
    Enzinger, Peter
    Qin, Shu-Kui
    Ferreira, Paula
    Chen, Jia
    Girotto, Gustavo
    de la Fouchardiere, Christelle
    Senellart, Helene
    Al-Rajabi, Raed
    Lordick, Florian
    Wang, Ruixue
    Suryawanshi, Shailaja
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35)
  • [50] KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%
    Brahmer, J.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Riccio, A.
    Yang, J.
    Pietanza, M. C.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S153 - S153
12345